menu
    • menu

    Company profile for Storm Therapeutics

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    Centrient is a leading manufacturer of Beta-Lactam Antibiotics and a provider of next-generation Statins and Antifungals.

    Virtual Booth

    Contact Supplier

    Moehs Group, a reference company in the production of pharmaceutical active ingredients.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases....
    STORM Therapeutics is a University of Cambridge spin-out, translating the ground-breaking work of Professors Tony Kouzarides and Eric Miska in RNA epigenetics into the discovery of first-in-class drugs in oncology and other diseases. It is the leading company currently tackling disease through modulating RNA modifying enzymes and is developing a unique platform to address these enzyme classes, including RNA methyltransferases. STORM is backed by blue chip investors Cambridge Innovation Capital, Merck Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group and Seroba Life Sciences who share the founders’ ambitions.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Storm Therapeuticsunitedkingdom_new Flag
    Country
    Country
    United Kingdom
    Address
    Address
    Babraham Research Campus, Moneta Building, Cambridge CB22 3AT
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.stormtherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/storm-therapeutics-limited
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/storm_tx

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    STORM Appoints Dr. Martin as Chief Development Officer
    STORM Appoints Dr. Martin as Chief Development Officer

    26 Jun 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/storm-therapeutics-appoints-veteran-cancer-drug-developer-dr-eric-martin-as-chief-development-officer-302492100.html

    PR NEWSWIRE
    26 Jun 2025
    Share Share
    Coherus & Storm therapeutics to Test STC-15 + LOQTORZI in Combo
    Coherus & Storm therapeutics to Test STC-15 + LOQTORZI in Combo

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088627/33333/en/Coherus-Announces-Clinical-Collaboration-with-STORM-Therapeutics-to-Evaluate-STC-15-in-Combination-with-LOQTORZI-toripalimab-tpzi.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share
    Storm Therapeutics Presents Data on METTL3 Inhibitor at SITC
    Storm Therapeutics Presents Data on METTL3 Inhibitor at SITC

    11 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/storm-therapeutics-presents-new-clinical-data-on-its-first-in-class-mettl3-inhibitor-stc-15-at-sitc-2024-302300175.html

    PR NEWSWIRE
    11 Nov 2024
    Share Share
    STORM's METTL3 Inhibitor STC-15 Interim Phase 1 Data At ASCO
    STORM's METTL3 Inhibitor STC-15 Interim Phase 1 Data At ASCO

    03 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/storm-therapeutics-presented-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024-302160864.html

    PR NEWSWIRE
    03 Jun 2024
    Share Share
    Storm Stc-15 Interim Phase 1: Asco 2024 Mettl3 Rna Methyltransferase
    Storm Stc-15 Interim Phase 1: Asco 2024 Mettl3 Rna Methyltransferase

    24 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/storm-therapeutics-to-present-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024-302154453.html

    PR NEWSWIRE
    24 May 2024
    Share Share
    STORM's to Present Ph1 Data on its METTL3 RNA Methyltransferase Inh. STC-15
    STORM's to Present Ph1 Data on its METTL3 RNA Methyltransferase Inh. STC-15

    24 May 2024

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2024-05-24/storm-therapeutics-to-present-interim-phase-1-clinical-data-on-its-mettl3-rna-methyltransferase-inhibitor-stc-15-at-asco-2024

    PHARMIWEB
    24 May 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search